Endogenous Subclinical Hyperthyroidism May Not Lead to Bone Loss in Premenopausal Women

Overview

Journal Hippokratia

Specialty General Medicine

Date 2015 Feb 20

PMID 25694759

Citations 5

Authors

T Saler

S Ahbab

Z A Saglam

S O Keskek

S Kurnaz

Affiliations

Soon will be listed here.

Abstract

Background: Osteoporosis is defined as the decrease in bone mineral density. It is a serious health problem showing the predisposed person with increased bone fracture risk. Hyperthyroidism is one of the major causes of secondary osteoporosis. The aim of this study was to assess bone mineral density in premenopausal women with endogenous subclinical hyperthyroidism.

Methods: A total of 168 subjects were included in this case-control study, of whom 86 and 82 participants were premenopausal women with subclinical hyperthyroidism and healthy premenopausal subjects, respectively. The patients with subclinical hyperthyroidism who were not receiving L-thyroxine treatment were included. The women in postmenopausal state or having chronic disease were excluded. The bone mineral densities of all subjects with dual energy X-ray absorptiometry were examined.

Results: The Z scores (femur and L1-4) of the study group were -0.15 ± 1.15 and -0.23 ± 1.03, respectively. The Z scores of the control group were -0.39 ± 1.08 and -0.55 ± 0.98, respectively. The differences between the groups were not statistically significant (p=0.14, 0.34, respectively).

Conclusion: Our data suggest that contrary to exogenous subclinical hyperthyroidism, endogenous subclinical hyperthyroidism may not decrease bone mineral density in premenopausal women and it may not a risk factor for osteopenia or osteoporosis. Hippokratia 2014; 18 (3): 240-244.

Citing Articles

Bone Mineral Density and Bone Turnover Marker in a Subclinical Thyrotoxic State in Young Premenopausal Women.

Lu C, Dharmalingam M, P R M, Y P G, Selvan C, Kalra P Cureus. 2024; 16(1):e52610.

PMID: 38374858 PMC: 10875710. DOI: 10.7759/cureus.52610.

Evaluation and Management of Bone Health in Patients with Thyroid Diseases: A Position Statement of the Korean Thyroid Association.

Hong A, Kang H Endocrinol Metab (Seoul). 2023; 38(2):175-189.

PMID: 37150514 PMC: 10164499. DOI: 10.3803/EnM.2023.1701.

Thyroid Hormone Diseases and Osteoporosis.

Delitala A, Scuteri A, Doria C J Clin Med. 2020; 9(4).

PMID: 32268542 PMC: 7230461. DOI: 10.3390/jcm9041034.

Subclinical thyroid dysfunction, bone mineral density, and osteoporosis in a middle-aged Korean population.

Lee K, Lim S, Park H, Woo H, Chang Y, Sung E Osteoporos Int. 2019; 31(3):547-555.

PMID: 31720711 DOI: 10.1007/s00198-019-05205-1.

The relationship between subclinical thyroid dysfunction and the risk of fracture or low bone mineral density: a systematic review and meta-analysis of cohort studies.

Yang R, Yao L, Fang Y, Sun J, Guo T, Yang K J Bone Miner Metab. 2017; 36(2):209-220.

PMID: 28357593 DOI: 10.1007/s00774-017-0828-5.

References

Faber J, Galloe A . Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol. 1994; 130(4):350-6. DOI: 10.1530/eje.0.1300350. View

Bassett J, OShea P, Sriskantharajah S, Rabier B, Boyde A, Howell P . Thyroid hormone excess rather than thyrotropin deficiency induces osteoporosis in hyperthyroidism. Mol Endocrinol. 2007; 21(5):1095-107. DOI: 10.1210/me.2007-0033. View

Tauchmanova L, Nuzzo V, Del Puente A, Fonderico F, Esposito-del Puente A, Padulla S . Reduced bone mass detected by bone quantitative ultrasonometry and DEXA in pre- and postmenopausal women with endogenous subclinical hyperthyroidism. Maturitas. 2004; 48(3):299-306. DOI: 10.1016/j.maturitas.2004.02.017. View

Lehmke J, Bogner U, Felsenberg D, Peters H, Schleusener H . Determination of bone mineral density by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopaenia in post-menopausal women. Clin Endocrinol (Oxf). 1992; 36(5):511-7. DOI: 10.1111/j.1365-2265.1992.tb02254.x. View

Mudde A, Reijnders F, Kruseman A . Peripheral bone density in women with untreated multinodular goitre. Clin Endocrinol (Oxf). 1992; 37(1):35-9. DOI: 10.1111/j.1365-2265.1992.tb02280.x. View

Faber J, Jensen I, Petersen L, Nygaard B, Hegedus L, Siersbaek-Nielsen K . Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin Endocrinol (Oxf). 1998; 48(3):285-90. DOI: 10.1046/j.1365-2265.1998.00427.x. View

Nilas L, Christiansen C . Rates of bone loss in normal women: evidence of accelerated trabecular bone loss after the menopause. Eur J Clin Invest. 1988; 18(5):529-34. DOI: 10.1111/j.1365-2362.1988.tb01052.x. View

Chabert-Orsini V, Conte-Devolx B, Denizot A, Audiffret J, Henry J, Codaccioni J . [Bone density after iatrogenic subclinical long-term thyrotoxicosis. Measurement by dual photon absorptiometry]. Presse Med. 1990; 19(37):1709-11. View

Mikosch P . [Effects of thyroid disorders on the bone]. Wien Med Wochenschr. 2006; 155(19-20):444-53. DOI: 10.1007/s10354-005-0222-0. View

10.

. Thyroxine replacement therapy--too much of a good thing?. Lancet. 1990; 336(8727):1352-3. View

11.

Foldes J, Tarjan G, Szathmari M, Varga F, KRASZNAI I, Horvath C . Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis?. Clin Endocrinol (Oxf). 1993; 39(5):521-7. DOI: 10.1111/j.1365-2265.1993.tb02403.x. View

12.

Khan A, Syed Z . Bone densitometry in premenopausal women: synthesis and review. J Clin Densitom. 2004; 7(1):85-92. DOI: 10.1385/jcd:7:1:85. View

13.

De Rosa G, Testa A, Giacomini D, Carrozza C, Astazi P, Caradonna P . Prospective study of bone loss in pre- and post-menopausal women on L-thyroxine therapy for non-toxic goitre. Clin Endocrinol (Oxf). 1998; 47(5):529-35. DOI: 10.1046/j.1365-2265.1997.3221125.x. View

14.

Gurlek A, Gedik O . Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Thyroid. 1999; 9(6):539-43. DOI: 10.1089/thy.1999.9.539. View

15.

Gorka J, Taylor-Gjevre R, Arnason T . Metabolic and clinical consequences of hyperthyroidism on bone density. Int J Endocrinol. 2013; 2013:638727. PMC: 3736466. DOI: 10.1155/2013/638727. View

16.

Diamond T, Nery L, HALES I . A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab. 1991; 72(6):1184-8. DOI: 10.1210/jcem-72-6-1184. View

17.

Rosario P . Bone and heart abnormalities of subclinical hyperthyroidism in women below the age of 65 years. Arq Bras Endocrinol Metabol. 2009; 52(9):1448-51. DOI: 10.1590/s0004-27302008000900007. View

18.

Uzzan B, Campos J, Cucherat M, Nony P, Boissel J, Perret G . Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab. 1996; 81(12):4278-89. DOI: 10.1210/jcem.81.12.8954028. View

19.

Ross D, Neer R, Ridgway E, Daniels G . Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med. 1987; 82(6):1167-70. DOI: 10.1016/0002-9343(87)90219-1. View

20.

Greenspan S, GREENSPAN F . The effect of thyroid hormone on skeletal integrity. Ann Intern Med. 1999; 130(9):750-8. DOI: 10.7326/0003-4819-130-9-199905040-00016. View